Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 19/20 | 0.70 |
| ▸ | RARB | P10826 | 18/20 | 0.70 |
| ▸ | RARA | P10276 | 17/20 | 0.70 |
| ▸ | RXRA | P19793 | 10/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arotinoid SCHEMBL2890176 | 1.00 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| Arotinoid SCHEMBL29430179 | 1.00 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9419002 | 0.95 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9419006 | 0.95 | RARG (0.63) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7547905 | 0.93 | RARB (0.59) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7547910 | 0.93 | RARB (0.59) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7087173 | 0.89 | RARG (0.61) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7087175 | 0.89 | RARG (0.61) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7085857 | 0.88 | RARG (0.67) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7085861 | 0.88 | RARG (0.67) | RARGRARBRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4326055-A | ANTITUMOR AGENTS, SKIN DISORDERS, RHEUMATIC DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1982-04-20 | — | — | US | claimed |
| EP-3152190-B1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC (US) | 2024-07-31 | — | — | EP | disclosed |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10752591-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | Haro Pharmaceuticals Inc. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180362467-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2018-12-20 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | HARO PHARMACEUTICAL INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2002032413-A2 | A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-1995033745-A9 | NOVEL COMPOUNDS USEFUL IN MODULATING GENE EXPRESSION OF RETINOID RESPONSIVE GENES AND/OR HAVING ANTI-AP-1 ACTIVITY | — | 1996-01-18 | — | — | WO | disclosed |
| EP-0510066-A4 | 1-AZETIDYL AND 1-HEXAMETHYLENIMINE ALKYL OR ARYL BISPHOSPHONIC ACIDS AND THEIR USE AS PHARMACOLOGICAL AGENTS | — | 1992-12-02 | — | — | EP | disclosed |
| EP-0510066-A1 | 1-AZETIDYL AND 1-HEXAMETHYLENIMINE ALKYL OR ARYL BISPHOSPHONIC ACIDS AND THEIR USE AS PHARMACOLOGICAL AGENTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991010646-A1 | 1-AZETIDYL AND 1-HEXAMETHYLENIMINE ALKYL OR ARYL BISPHOSPHONIC ACIDS AND THEIR USE AS PHARMACOLOGICAL AGENTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| US-4942157-A | CALCIUM METABOLISM, BONE DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-07-17 | — | — | US | disclosed |
| EP-0155940-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985000806-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-02-28 | — | — | WO | disclosed |
| US-4326055-A | ANTITUMOR AGENTS, SKIN DISORDERS, RHEUMATIC DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4316983-A | Neoplasmic compounds: sugar esters and glycosides | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752591-B2 | 18-20 member bi-polycyclic compounds | TNNI3, TNNC1, MYLK2 | RARG 4129/4885RARB 3587/4885RARA 4139/4885 |
| US-10377715-B2 | 18-20 member bi-polycyclic compounds | CKMT1A; CKMT1B, MYLK2, CPT1B | RARG 845/4885RARB 1026/4885RARA 1809/4885 |
| US-20180362467-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | CKMT1A; CKMT1B, MYLK2, CPT1B | RARG 845/4885RARB 1026/4885RARA 1809/4885 |
| US-10954194-B2 | 18-20 member bi-polycyclic compounds | BRCA1, UGT2B17, TP53 | RARG 862/4885RARB 1128/4885RARA 1079/4885 |
| US-20170114019-A1 | 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS | CKMT1A; CKMT1B, MYLK2, CPT1B | RARG 845/4885RARB 1026/4885RARA 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.